Similar reduction of glutathione levels was also observed in glioma bearing IDH1 or IDH2 mutation which accumulates 2-HG, suggesting that this oncometabolite may support ROS formation through attenuating the anti-oxidant system [63]. The gene discussed is IDH2; the disease is central nervous system cancer.